Conversely, Ozempics dosage tops out at 2 mg weekly, optimized primarily for glycemic control in type 2 diabetes, though it also offers significant weight reduction
If youre a high performer, physique enthusiast or high-level lifestyle client looking to elevate your approach, this episode will give you the full framework
In March 2024, Wegovy (semaglutide) was approved by the FDA to reduce the risk of major adverse cardiovascular events in adults with known heart disease and with obesity or overweight, in addition to a reduced calorie diet and increased physical activity
The LEADER cardiovascular outcomes trial demonstrated cardiovascular benefits, and subsequent analyses have shown reductions in inflammatory biomarkers
One recent example clearly illustrates this dedication
Sitagliptin was the first agent introduced (in 2006) with other substances having followed soon after